- Conditions
- Hidradenitis Suppurativa (HS)
- Interventions
- Radiated axilla
- Radiation
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Cherry Hill, New Jersey • Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2545–2568
of 5,327
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Advanced Solid Tumors, Lymphoid Malignancies
- Interventions
- Bardoxolone methyl
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Cleveland, Ohio • Houston, Texas
- Conditions
- Opioid Use, Pain, Postoperative, Opioid Use, Unspecified, Trauma, Opioid-use Disorder
- Interventions
- Provide assistance to subject's rural PCP pertaining to subject/patient pain management goals and opioid taper plan
- Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Cancer
- Interventions
- rovalpituzumab tesirine
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 3
- States / cities
- Tucson, Arizona • Duarte, California • Pittsburgh, Pennsylvania
- Conditions
- Leiomyosarcoma
- Interventions
- Unesbulin, Dacarbazine, Placebo
- Drug · Other
- Lead sponsor
- PTC Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 359 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 23
- States / cities
- Duarte, California • Los Angeles, California • Santa Monica, California + 18 more
- Conditions
- Mucosal Melanoma, Recurrent Melanoma, Stage IV Melanoma
- Interventions
- temsirolimus, selumetinib, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Adjunctive Treatment of Major Depressive Disorder
- Interventions
- Pimavanserin, Placebo
- Drug · Other
- Lead sponsor
- ACADIA Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 207 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Rogers, Arkansas • Garden Grove, California + 31 more
- Conditions
- Disseminated Neuroblastoma, Recurrent Neuroblastoma
- Interventions
- pyrazoloacridine, filgrastim, autologous bone marrow transplantation, peripheral blood stem cell transplantation, laboratory biomarker analysis, pharmacological study
- Drug · Biological · Procedure + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Healthy
- Interventions
- EDP-788, Placebo
- Drug
- Lead sponsor
- Enanta Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Dociparstat, Control
- Drug · Other
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 14
- States / cities
- Orange, California • Westwood, Kansas • Louisville, Kentucky + 11 more
- Conditions
- Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder
- Interventions
- Amphetamine, ESDM informed parent coaching, Placebo Oral Tablet
- Drug · Behavioral
- Lead sponsor
- Duke University
- Other
- Eligibility
- 36 Months to 131 Months
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Transplant Failure or Rejection of Bone Marrow (Graft vs Host Disease, GVHD)
- Interventions
- Ruxolitinib, LBP- MARCO
- Drug · Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Breast Cancer
- Interventions
- Herceptin, Taxol, Fluorouracil, Cytoxan, Epirubicin
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2011
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Colorectal Cancer
- Interventions
- Tivozanib, Bevacizumab, mFOLFOX6
- Drug
- Lead sponsor
- AVEO Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 265 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 27
- States / cities
- Gilbert, Arizona • Hot Springs, Arizona • Tucson, Arizona + 22 more
- Conditions
- Endometrial Cancer
- Interventions
- Carboplatin/Paclitaxel, Trastuzumab
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- Female only
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2022
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Concord, California + 16 more
- Conditions
- Major Depressive Disorder
- Interventions
- Placebo, Cariprazine
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 819 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 39
- States / cities
- Garden Grove, California • National City, California • Oceanside, California + 34 more
- Conditions
- Primary Biliary Cholangitis
- Interventions
- Seladelpar, PTM Seladelpar, Cilofexor Dose B, PTM Cilofexor Dose A, PTM Cilofexor Dose B, Cilofexor Dose A
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2034
- U.S. locations
- 4
- States / cities
- Colorado Springs, Colorado • Lakewood Rch, Florida • Atlanta, Georgia + 1 more
- Conditions
- Pain
- Interventions
- Ketamine, Opioids
- Drug
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Anemia
- Interventions
- Mircera, Darbepoetin alfa
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 228 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 11
- States / cities
- Granada Hills, California • Lauderdale Lakes, Florida • Augusta, Georgia + 8 more
- Conditions
- Recurrent and Refractory Solid Tumors
- Interventions
- Lenvatinib, Everolimus
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 42 more
- Conditions
- Malignant Pleural Mesothelioma
- Interventions
- Pembrolizumab, IMPRINT
- Drug · Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- brca1 Mutation Carrier, brca2 Mutation Carrier, Breast Cancer
- Interventions
- therapeutic estradiol, deslorelin, therapeutic testosterone, therapeutic conventional surgery, active surveillance, quality-of-life assessment, laboratory biomarker analysis
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 21 Years to 48 Years · Female only
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2024
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Polycythemia Vera
- Interventions
- Erlotinib
- Drug
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Thalassemia Major
- Interventions
- DST-0509, Jadenu, Exjade
- Drug
- Lead sponsor
- DisperSol Technologies, LLC
- Industry
- Eligibility
- 8 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York